Connect with us

Business

Craig Fischer Of Demand Brands Inc (OTCPK:DMAN) Issues An Update To The Shareholders On Future Oil And Gas Operations

Published

on

Craig Fischer, Chief Executive Officer of Demand Brands Inc (OTCPK:DMAN), is pleased to issue an update on the future oil and gas operations and Hageilstein Ranch lease prospect to the shareholders. The company is conducting business as GeoEnhanced Technologies Inc.

GeoEnhanced holds Southwest Texas-based Hageilstein Ranch lease, which is situated 15 miles north to the Mexican border. There are no oil and gas producing wells in this area. However, it finds consistent geographical formations in the neighboring nation’s active oil fields.

Receives a lease option on 10,000 acres

GeoEnhanced has received a lease option on close to 10,000 acres of property in 2017. The company has been conducting electro-seismic surveys on this property continuously. Its team again visited the area and surveyed more than 30 locations in three days to confirm data from the previous visits. The company’s main aim is to confirm the presence of viable water and hydrocarbon resources on this property.

Chief Geologist of GeoEnhanced, Adrian Garcia said the studies confirmed the presence of via reserves at a depth of between 3,500 Ft. and 4,000 Ft. However, he has not provided an estimate of the size of the reserves. The team needs to find the porosity, breadth, and direction of flow. In the next step, the team will find the appropriate location for drilling and maximize production. It will be able to identify the reserve numbers and producible zones going forward.

Final note

Craig said the final study will be conducted in February 2020 and expecting to make the first drill by the end of Q2 2020. The formation in this region is part of a bigger basin. It expects daily oil production yields of 100 to 300 barrels. However, the company will confirm the yields only after testing. GeoEnhanced expects up to three wells in a 100 acres area. The team will conduct further studies in the balance area for drilling opportunities. 2020’s first half is an exciting period for the company in identifying the oil and gas reserves.

Acquires 100% stake in GeoEnhanced

Demand Brands has acquired a 100% stake in GeoEnhanced by issuing its 100,000 series A preferred stock. It will not cause any dilution to the shareholders of Demand Brands. Established in 2016, GeoEnhanced is engaged in the development and marketing of a 4D seismic imaging system for exploring oil, water, minerals, and gas.

Business

TerrAscend Canada Inc, A Subsidiary Of Terrascend Corp (OTCMKTS:TRSSF), Enters A $80.5 Million CAD Loan Financing Accord With Canopy Growth Corp (NYSE:CGC)

Published

on

TerrAscend Canada Inc, a subsidiary of Canopy Rivers Inc (OTCMKTS:CNPOF), has entered into an $80.5 Million CAD loan financing agreement with Canopy Growth Corp (NYSE:CGC). As per the terms of the deal, Canopy Growth has received 17.8 million common shares purchase warrants from TerrAscend.

Well-positioned to capitalize on opportunities

CEO and President of Canopy Rivers, Narbe Alexandrian, said it shows the confidence in TerrAscend’s capability to implement the strategic mandate for domestic and international markets. He said the team at TerrAscend is well-positioned to leverage the flourishing opportunities in the regulated jurisdictions using its network and resources. Narbe is pleased with the support extended by Canopy Growth for its portfolio company – TerrAscend.

Proceeds for general corporate purposes

TerrAscend Canada will use the proceeds to fund the Canadian operations and for general corporate purposes. It will also use the funds to repay indebtedness and to support global expansion and its Arise Bioscience U.S. hemp division.

Receives a permit to cultivate medical marijuana

TerrAscend has announced the receipt of a permit from the New Jersey Department of Health to cultivate medical marijuana. Its subsidiary TerrAscend NJ will commence the cultivation immediately at its facility situated in Boonton Township, northern New Jersey. It is the second entity in New Jersey among the six applicants selected in December 2018 by the Department of Health. TerrAscend NJ can commence manufacturing after the receipt of dispensing and additional processing approvals. It can manage up to three dispensaries in the northern area of New Jersey.

66,000 patients’ gains access to the medical marijuana program

More than 66,000 patients have gained access to the medical marijuana program as of January 2020 in New Jersey. The registered medical patients’ count has almost tripled since early 2018.

TerrAscend has purchased a sixteen-acre site in Boonton Township. It commenced the construction on an area of 227,000 Sq. Ft. under the first phase to cover cultivation, support space, and processing on 80,000 Sq. Ft. The first phase will become operational in H1 2020.

TerrAscend will supply the wholesale customers and its dispensaries by sourcing the cannabis products from its scaled cultivation capacity. It also expects to meet the demand for fifteen new retail dispensaries using cannabis from the scaled cultivation facility.

Continue Reading

Business

Medipharm Labs Corp (OTCMKTS:MEDIF) Expects To Begin Supply Of Pharmaceutical-quality cannabis oil products in Australia

Published

on

Medipharm Labs Corp (OTCMKTS:MEDIF) will supply pharmaceutical quality cannabis oil products in Australia. It is on the backdrop of a two-year agreement signed between Compass Clinics Australia Pty Ltd and MediPharm Labs Australia Pty Ltd.

Provides education and consultation services

Compass Clinics provides education and consultation services to Australian patients who look to access medical cannabis products. The company inaugurated its first two clinics last year in Australia. It will now commence the sale of its own branded products. Compass Clinics expects to inaugurate additional clinics in 2020. It offers consultation services for the patients, who want to get medical cannabis products via SAS (Special Access Scheme) or Authorized Prescriber pathways, in Australia. The company also uses the services of third-parties to sell cannabis oil and cannabis products.

Complies with minimum requirements to import cannabis

Chief Executive Officer of Medipharm Labs, Pat McCutcheon, said the company is excited to work with leading players like Compass Clinics to provide high-quality cannabis products to medical patients in Australia. The partnership with Cannabis Clinics helps the company to comply with the minimum requirements set by the Australian Government to import cannabis products.

Recently received import licenses, and Australian GMP certification helps the company to increase demand for its Pharma quality products. It also helps to expand its presence in the emerging worldwide markets and Australia.

Distribution of cannabis oil products in Australia

Medipharm Labs Australia will commence the supply of white-labeled cannabis oil under the trademark of Compass Clinics. The company will start receiving the formulated cannabis oil products from the Canadian TGA GMP certified facility of Medipharm Labs. It will distribute imported cannabis oil products to Compass Clinics in Australia.

President of Compass Clinics, David Martyn, said the company is pleased to offer GMP certified best-in-class, and pharmaceutical grade gel caps and cannabis oils to the growing patient base in Australia. He said Compass Clinics will benefit from its association with a leading producer of cannabis products – Medipharm Labs in serving its prevailing patient base. It also helps to expand its footprint in the surging medical cannabis space worldwide.

New scheduling status for CBD

The Australian authorities expect to consider a new scheduling status for cannabidiol. It expects to ensure the availability of CBD in low dosages early this year. The TGA is currently reviewing the safety of lower dosages of CBD.

Continue Reading

Business

Kannalife Inc (OTCMKTS:KLFE) Announces Receipt Of Australian Patent To Treat Hepatic Encephalopathy

Published

on

Kannalife Inc (OTCMKTS:KLFE), a portfolio company of Medical Marijuana Inc (OTCMKTS:MJNA), has received an Australian patent No. AU2015204609B2, which is specific to the Novel Functionalized 1,3-Benzene Diols as well as their method to cure Hepatic Encephalopathy. Kannalife owns seven patents across the world.

Committed to widen cannabis knowledge

Chief Executive Officer of Medical Marijuana, Dr. Stuart Titus, said Kannalife and Medical Marijuana are committed to accepting cannabinoid and cannabis-related studies and widening knowledge worldwide. Kannalife is embarked on this target with new patients in six nations.

KLS-13019, a leading candidate in the intellectual property of Kannalife, can act as a neuroprotective agent to cure a wide range of diseases that comprise neurodegenerative disorders, oxidative stress, and nervous system disorders. Chief Executive Officer of Kannalife, Dean Petkanas, said the company is pleased that several jurisdictions recognized its Intellectual Estate as proprietary and novel.

The patent is vital to commercialize KLS-13019

The receipt of an Australian Patent is an important step in gearing towards commercializing its leading drug candidate – KLS-13019 soon. It expects to market the drug in the pharmaceutical market of Australia. The demand for Australian pharmaceuticals expects to reach $32.1 billion this year.

After applying for PCT patent in 2015, Kannalife received the following patents:

The US Patent No 10,044,722 “a method to cure hepatic encephalopathy or diseases related to the free radical medical stress as well as oxidative stress using novel functionalized 1,3-benzene diols.”

The US Patent No 9,611,213 “an innovative functionalized 1,3-Benzene Diols and their methods to cure hepatic encephalopathy”.

The company also received Russian and Japanese patents.

Kannalife commences trading on the OTC markets

Kannalife is pleased to announce that it commences trading under the ticker symbol – KLFE on the OTC markets. After becoming an investor in Kannalife in 2013, Medical Marijuana now holds a stake of 26.17%.

Stuart said the company is excited that the general public and investors can contribute to the funding of Kannalife’s R&D programme in cannabinoid-therapeutics. The market for cannabinoid-based pharmaceuticals in the US expects to reach $50 billion in the next decade. Marijuana, as an early investor in Kannalife, believes that its portfolio of IP assets and ground-breaking research helps the company to stay ahead in the race.

Continue Reading

FEATURED STORIES

Business8 hours ago

TerrAscend Canada Inc, A Subsidiary Of Terrascend Corp (OTCMKTS:TRSSF), Enters A $80.5 Million CAD Loan Financing Accord With Canopy Growth Corp (NYSE:CGC)

Post Views: 167 TerrAscend Canada Inc, a subsidiary of Canopy Rivers Inc (OTCMKTS:CNPOF), has entered into an $80.5 Million CAD...

Business1 day ago

Medipharm Labs Corp (OTCMKTS:MEDIF) Expects To Begin Supply Of Pharmaceutical-quality cannabis oil products in Australia

Post Views: 392 Medipharm Labs Corp (OTCMKTS:MEDIF) will supply pharmaceutical quality cannabis oil products in Australia. It is on the...

Business2 days ago

Kannalife Inc (OTCMKTS:KLFE) Announces Receipt Of Australian Patent To Treat Hepatic Encephalopathy

Post Views: 308 Kannalife Inc (OTCMKTS:KLFE), a portfolio company of Medical Marijuana Inc (OTCMKTS:MJNA), has received an Australian patent No....

Business3 days ago

SinglePoint, Inc. (OTCMKTS:SING) Unveils Hemp Seed Oil Infused Hand Sanitizer – Klen Hands To Combat Coronavirus

Post Views: 397 SinglePoint, Inc. (OTCMKTS:SING) has unveiled hemp seed oil infused hand sanitizer – Klen Hands to help people...

Business6 days ago

CV Sciences Inc (OTCMKTS:CVSI) Reports Revenues Of $53.7 Million In 2019: Increases Retail Distribution Footprint To Over 5,500 Stores

Post Views: 662 CV Sciences Inc (OTCMKTS:CVSI) has reported revenues of $53.7 million (up 11%) in 2019. It also increased...

Business1 week ago

Aleafia Health Inc (OTCMKTS:ALEAF) Reports Robust Revenues Of $6.028 Million In Q4 2019

Post Views: 424 Aleafia Health Inc (OTCMKTS:ALEAF) has reported revenues of $6.028 million in Q4 2019. It is an increase...

Whats Hot